董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ying Huang | 男 | Chief Executive Officer and Director | 52 | 未披露 | 7.53 | 2025-08-18 |
| Fangliang Zhang | 男 | Chairman of the Board | 61 | 未披露 | 106.74 | 2025-08-18 |
| Ye Wang | 女 | Director | 57 | 未披露 | 0.0016 | 2025-08-18 |
| Darren Xiaohui Ji | 男 | Independent Director | 62 | 未披露 | 3.14 | 2025-08-18 |
| Corazon D. Sanders | 女 | Independent Director | 68 | 未披露 | 3.14 | 2025-08-18 |
| Yau Wai Man Philip | 男 | Independent Director | 48 | 未披露 | 3.14 | 2025-08-18 |
| Li Zhu | 男 | Director | 75 | 未披露 | 未持股 | 2025-08-18 |
| Patrick Casey | 男 | Independent Director | 69 | 未披露 | 2.00 | 2025-08-18 |
| Li Mao | 男 | Independent Director | 68 | 未披露 | 未持股 | 2025-08-18 |
| Tomas Heyman | 男 | Independent Director | 69 | 未披露 | 未持股 | 2025-08-18 |
| Peter Salovey | -- | Independent Director | 67 | 未披露 | 未持股 | 2025-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ying Huang | 男 | Chief Executive Officer and Director | 52 | 未披露 | 7.53 | 2025-08-18 |
| Carlos Santos | 男 | Chief Financial Officer, principal accounting officer | -- | 未披露 | 未持股 | 2025-08-18 |
董事简历
中英对照 | 中文 | 英文- Ying Huang
-
Ying Huang自2019年7月起担任我们的首席财务官。在加入我们之前，黄博士于2014年8月至2019年7月担任美国银行证券公司（BofA Securities，Inc.）董事总经理兼生物技术股票研究主管，在那里他领导了一支涵盖30多家生物技术公司的分析师团队，包括Amgen，Gilead，Celgene，Biogen和其他涵盖广泛治疗领域的药物。黄博士自2007年以来一直担任生物技术分析师，在加入美国银行证券公司（BofA Securities，Inc.）之前，曾在Wells Fargo（前身为Wachovia，Credit Suisse，Gleacher和Barclays）工作。在他的华尔街职业生涯之前，Huang博士是Schering-Plough（现Merck&Co.）化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。他也是多个专利和同行评议出版物的合著者。Huang博士拥有Columbia University生物有机化学博士学位。黄博士还曾就读于哥伦比亚商学院和中国科技大学天才青年特别班。
Ying Huang,has served as chief executive officer since September 2020 and previously served as chief financial officer from July 2019 until May 2022. Dr. Huang has also been a director of Quanta Therapeutics, Inc., a privately-held company, since February 2022. Prior to joining Legend Biotech Corporation , Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. In December 2021, Dr. Huang was appointed to board of directors as a Class I director. - Ying Huang自2019年7月起担任我们的首席财务官。在加入我们之前，黄博士于2014年8月至2019年7月担任美国银行证券公司（BofA Securities，Inc.）董事总经理兼生物技术股票研究主管，在那里他领导了一支涵盖30多家生物技术公司的分析师团队，包括Amgen，Gilead，Celgene，Biogen和其他涵盖广泛治疗领域的药物。黄博士自2007年以来一直担任生物技术分析师，在加入美国银行证券公司（BofA Securities，Inc.）之前，曾在Wells Fargo（前身为Wachovia，Credit Suisse，Gleacher和Barclays）工作。在他的华尔街职业生涯之前，Huang博士是Schering-Plough（现Merck&Co.）化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。他也是多个专利和同行评议出版物的合著者。Huang博士拥有Columbia University生物有机化学博士学位。黄博士还曾就读于哥伦比亚商学院和中国科技大学天才青年特别班。
- Ying Huang,has served as chief executive officer since September 2020 and previously served as chief financial officer from July 2019 until May 2022. Dr. Huang has also been a director of Quanta Therapeutics, Inc., a privately-held company, since February 2022. Prior to joining Legend Biotech Corporation , Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. In December 2021, Dr. Huang was appointed to board of directors as a Class I director.
- Fangliang Zhang
-
Fangliang Zhang自2015年5月以来一直担任我们的董事会主席。Zhang博士自2015年以来一直担任GenScript的董事长，执行董事兼首席执行官。他于2002年共同创立GenScript Group，并一直担任多种集团公司的董事（2015年GenScript公司首次公开发行的公司重组之后，GenScript公司成为集团公司的控股公司）。2015年，张博士成立了我们公司，作为GenScript的子公司，扩大了GenScript的业务目标，以研究，制造和商业化广泛的免疫疗法。2018年，张博士在中国梦百合峰会上被授予年度人物，以表彰他对梦百合领域的贡献和重大影响。张博士还撰写了20多篇发表在同行评审期刊上的文章，是9项科学专利的发明人。创立GenScript公司之前，他曾担任Schering-Plough公司的首席科学家（从1995年到2002年），在那里他曾获得总裁奖。张博士拥有杜克大学生物化学博士学位，南京大学硕士学位和成都地质学院学士学位。
Fangliang Zhang,has served as director and chairman of board of directors since August 2022. Dr. Zhang has been an executive director of GenScript since December 2022 and, prior that, was a non-executive director of GenScript from May 2022 to December 2022. Prior to that time, he was chairman and an executive director of GenScript from 2015 to 2020. He also serves as the CEO of certain companies within the Genscript group. He co-founded the GenScript group in 2002 and has been the director of various group companies prior to GenScript becoming the holding company of the group companies pursuant to the corporate reorganization for GenScript's initial public offering in 2015. In 2015, Dr. Zhang founded the Company as a subsidiary of GenScript, expanding GenScript's business goal to research, manufacture and commercialize a broad range of immunotherapy treatments. Dr. Zhang served as Chairman of board of directors from 2015 to November 2020 and served as Chief Executive Officer from August 2020 to September 2020. In 2018, Dr. Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field. Before founding GenScript, Dr. Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr. Zhang holds a Ph.D. in biochemistry from Duke University, a Master's degree from Nanjing University and a Bachelor's degree from Chengdu Institute of Geology. - Fangliang Zhang自2015年5月以来一直担任我们的董事会主席。Zhang博士自2015年以来一直担任GenScript的董事长，执行董事兼首席执行官。他于2002年共同创立GenScript Group，并一直担任多种集团公司的董事（2015年GenScript公司首次公开发行的公司重组之后，GenScript公司成为集团公司的控股公司）。2015年，张博士成立了我们公司，作为GenScript的子公司，扩大了GenScript的业务目标，以研究，制造和商业化广泛的免疫疗法。2018年，张博士在中国梦百合峰会上被授予年度人物，以表彰他对梦百合领域的贡献和重大影响。张博士还撰写了20多篇发表在同行评审期刊上的文章，是9项科学专利的发明人。创立GenScript公司之前，他曾担任Schering-Plough公司的首席科学家（从1995年到2002年），在那里他曾获得总裁奖。张博士拥有杜克大学生物化学博士学位，南京大学硕士学位和成都地质学院学士学位。
- Fangliang Zhang,has served as director and chairman of board of directors since August 2022. Dr. Zhang has been an executive director of GenScript since December 2022 and, prior that, was a non-executive director of GenScript from May 2022 to December 2022. Prior to that time, he was chairman and an executive director of GenScript from 2015 to 2020. He also serves as the CEO of certain companies within the Genscript group. He co-founded the GenScript group in 2002 and has been the director of various group companies prior to GenScript becoming the holding company of the group companies pursuant to the corporate reorganization for GenScript's initial public offering in 2015. In 2015, Dr. Zhang founded the Company as a subsidiary of GenScript, expanding GenScript's business goal to research, manufacture and commercialize a broad range of immunotherapy treatments. Dr. Zhang served as Chairman of board of directors from 2015 to November 2020 and served as Chief Executive Officer from August 2020 to September 2020. In 2018, Dr. Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field. Before founding GenScript, Dr. Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr. Zhang holds a Ph.D. in biochemistry from Duke University, a Master's degree from Nanjing University and a Bachelor's degree from Chengdu Institute of Geology.
- Ye Wang
-
Ye Wang自2015年5月起担任我们的董事。王女士自2015年以来一直担任GenScript的首席运营官，自2009年以来一直担任GenScript的董事会成员，并自2017年12月以来一直担任GenScript的总裁，负责GenScript的战略和整体运营管理。她于2002年共同创立GenScript Group，并曾担任GenScript Corporation的多种管理职务，此前GenScript公司成为集团公司的控股公司。加入GenScript公司之前，她曾担任Shenzhen Futty Environmental Protection Surveillance Station的环境监测工程师。王女士拥有武汉大学硕士学位，布里奇波特大学计算机科学硕士学位和中欧国际工商学院执行工商管理硕士学位。
Ye Wang,has served as director since May 2015 and from November 2020 to August 2022 was the chairwoman of board of directors. Ms. Wang served as the Chief Operating Officer of Genscript from April 2014 to November 2017, has served on Genscript's board of directors since 2009 and has served as Genscript's President since December 2017, responsible for Genscript's strategies and overall operational management. She co-founded the Genscript group in 2002 and has taken various managerial positions in Genscript Corporation before Genscript became the holding company of the Genscript group of companies. Prior to joining Genscript, she worked as an Environmental Monitoring Engineer at Shenzhen Futian Environment Protection Surveillance Station. Ms. Wang is a Partner for Nanjing Genbest Enterprise Management Center and is a Trustee and President of Ren-Shiu Foundation, Inc. Ms. Wang holds an M.S. degree from Wuhan University, a Master's degree in Computer Sciences from the University of Bridgeport and an Executive M.B.A degree from the China Europe International Business School. - Ye Wang自2015年5月起担任我们的董事。王女士自2015年以来一直担任GenScript的首席运营官，自2009年以来一直担任GenScript的董事会成员，并自2017年12月以来一直担任GenScript的总裁，负责GenScript的战略和整体运营管理。她于2002年共同创立GenScript Group，并曾担任GenScript Corporation的多种管理职务，此前GenScript公司成为集团公司的控股公司。加入GenScript公司之前，她曾担任Shenzhen Futty Environmental Protection Surveillance Station的环境监测工程师。王女士拥有武汉大学硕士学位，布里奇波特大学计算机科学硕士学位和中欧国际工商学院执行工商管理硕士学位。
- Ye Wang,has served as director since May 2015 and from November 2020 to August 2022 was the chairwoman of board of directors. Ms. Wang served as the Chief Operating Officer of Genscript from April 2014 to November 2017, has served on Genscript's board of directors since 2009 and has served as Genscript's President since December 2017, responsible for Genscript's strategies and overall operational management. She co-founded the Genscript group in 2002 and has taken various managerial positions in Genscript Corporation before Genscript became the holding company of the Genscript group of companies. Prior to joining Genscript, she worked as an Environmental Monitoring Engineer at Shenzhen Futian Environment Protection Surveillance Station. Ms. Wang is a Partner for Nanjing Genbest Enterprise Management Center and is a Trustee and President of Ren-Shiu Foundation, Inc. Ms. Wang holds an M.S. degree from Wuhan University, a Master's degree in Computer Sciences from the University of Bridgeport and an Executive M.B.A degree from the China Europe International Business School.
- Darren Xiaohui Ji
-
Darren Xiaohui Ji自2020年5月起担任我们的董事。季博士目前担任Elpiscience Biopharmaceuticals，Inc.的首席执行官兼董事长，该公司是他于2017年6月共同创立的临床阶段免疫疗法公司。他也是Lilly Asia Ventures LAV的风险合伙人，他自2017年1月起担任该职位。在此之前，季博士于2013年至2016年12月担任F.Hofmann-La Roche Ltd.亚洲和新兴市场业务发展全球主管兼Vice President。季博士于1997年至2007年在宝洁制药公司（Procter&Gamble Pharmaceuticals）开始其职业生涯，负责药物研发和业务发展。他随后于2008年共同创立并管理上海PharmaLegacy Laboratories公司，担任首席执行官。2005年以来，他也曾一直担任the Bayhelix Group（生命科学中国遗产的商业领袖社区）的董事会成员。季博士拥有中国医科大学的医学博士学位，英国谢菲尔德大学的博士学位和芝加哥大学的工商管理硕士学位。
Darren Xiaohui Ji,has served as director since May 2020. Dr. Ji currently serves as chief executive officer and chairman of the board of directors of Elpiscience Biopharmaceuticals, Inc., a clinical stage immunotherapy company that he co-founded in June 2017. He also served as a Venture Partner of Lilly Asia Ventures (LAV), a position he held from January 2017 to December 2019. Prior to that, Dr. Ji was Global Head and Vice President of Business Development in Asia and Emerging Markets at F. Hofmann-La Roche Ltd. from 2013 to December 2016. Dr. Ji started his career at Procter & Gamble Pharmaceuticals with responsibilities in drug R&D and business development from 1997 to 2007. He then co-founded and managed as chief executive officer of PharmaLegacy Laboratories in Shanghai in 2008. From 2008 to 2013, he served as a board member of the BayHelix Group, a community of business leaders of Chinese Heritage in life science. Dr. Ji holds an M.D. from China Medical University, a Ph.D. from University of Sheffield in the United Kingdom and an M.B.A. from the University of Chicago. - Darren Xiaohui Ji自2020年5月起担任我们的董事。季博士目前担任Elpiscience Biopharmaceuticals，Inc.的首席执行官兼董事长，该公司是他于2017年6月共同创立的临床阶段免疫疗法公司。他也是Lilly Asia Ventures LAV的风险合伙人，他自2017年1月起担任该职位。在此之前，季博士于2013年至2016年12月担任F.Hofmann-La Roche Ltd.亚洲和新兴市场业务发展全球主管兼Vice President。季博士于1997年至2007年在宝洁制药公司（Procter&Gamble Pharmaceuticals）开始其职业生涯，负责药物研发和业务发展。他随后于2008年共同创立并管理上海PharmaLegacy Laboratories公司，担任首席执行官。2005年以来，他也曾一直担任the Bayhelix Group（生命科学中国遗产的商业领袖社区）的董事会成员。季博士拥有中国医科大学的医学博士学位，英国谢菲尔德大学的博士学位和芝加哥大学的工商管理硕士学位。
- Darren Xiaohui Ji,has served as director since May 2020. Dr. Ji currently serves as chief executive officer and chairman of the board of directors of Elpiscience Biopharmaceuticals, Inc., a clinical stage immunotherapy company that he co-founded in June 2017. He also served as a Venture Partner of Lilly Asia Ventures (LAV), a position he held from January 2017 to December 2019. Prior to that, Dr. Ji was Global Head and Vice President of Business Development in Asia and Emerging Markets at F. Hofmann-La Roche Ltd. from 2013 to December 2016. Dr. Ji started his career at Procter & Gamble Pharmaceuticals with responsibilities in drug R&D and business development from 1997 to 2007. He then co-founded and managed as chief executive officer of PharmaLegacy Laboratories in Shanghai in 2008. From 2008 to 2013, he served as a board member of the BayHelix Group, a community of business leaders of Chinese Heritage in life science. Dr. Ji holds an M.D. from China Medical University, a Ph.D. from University of Sheffield in the United Kingdom and an M.B.A. from the University of Chicago.
- Corazon D. Sanders
-
Corazon D. Sanders博士，自2020年起担任百济神州有限公司独立非执行董事，目前还担任百济神州有限公司董事会审计委员会成员、科学咨询委员会成员、商业及医学事务咨询委员会成员。Sanders博士于1979年取得菲律宾大学统计学理学学士及理学硕士学位，并于1989年取得宾夕法尼亚大学沃顿商学院统计学硕士及博士学位。1994年至2017年，Sanders博士于Genentech/罗氏担任多项领导职位，包括担任Genentech/罗氏后期组合委员会（Late Stage Portfolio Committee）成员、Genentech/罗氏后期临床业务部（Late Stage Clinical Operations）全球总监及Genentech/罗氏生物测定组全球总监，并在Genentech被罗氏收购前担任Genentech DATA（设计、分析、技术及管理部）主管。2017年至2018年，其担任Juno Therapeutics执行委员会成员，并担任开发业务部执行副总裁，负责战略运营、定量科学、生物样品及临床业务。2018年至2019年，Sanders博士担任新基首席医疗官办公室的战略顾问。2019年至2020年，其担任百时美施贵宝全球开发小组过渡期临时顾问。自2019年至2024年12月，Sanders博士担任Molecular TemplatesInc.董事。自2020年至今担任Legend Biotech Corporation董事，自2021年6月至今担任Ultragenyx PharmaceuticalInc.董事。Sanders博士目前还担任AltruBioInc.的董事。
Corazon D. Sanders,has served as director since May 2020. Dr. Sanders has been a member of AltruBio Inc. (f/k/a AbGenomics Holdings Inc.) since March 2020, of Beigene, Ltd since August 2020, and of Ultragenyx Pharmaceuticals, Inc. since June 2021. She was on the board of directors of Molecular Templates, Inc. from December 2019 to December 2024. Dr. Sanders previously served as a Strategic Advisor to the Office of the Celgene Chief Medical Officer from March 2018 to November 2019. Prior to that, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations from January 2017 to March 2018. Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2009 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017. Dr. Sanders also served on the Board of Trustees of the Fred Hutchinson Cancer Research Center and has been the co-chair of the board of Advisors of the newly created Fred Hutchinson Research Center since 2022. Dr. Sanders holds a B.S. and M.S. in statistics, graduating Magna Cum Laude from the University of the Philippines, and an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania. - Corazon D. Sanders博士，自2020年起担任百济神州有限公司独立非执行董事，目前还担任百济神州有限公司董事会审计委员会成员、科学咨询委员会成员、商业及医学事务咨询委员会成员。Sanders博士于1979年取得菲律宾大学统计学理学学士及理学硕士学位，并于1989年取得宾夕法尼亚大学沃顿商学院统计学硕士及博士学位。1994年至2017年，Sanders博士于Genentech/罗氏担任多项领导职位，包括担任Genentech/罗氏后期组合委员会（Late Stage Portfolio Committee）成员、Genentech/罗氏后期临床业务部（Late Stage Clinical Operations）全球总监及Genentech/罗氏生物测定组全球总监，并在Genentech被罗氏收购前担任Genentech DATA（设计、分析、技术及管理部）主管。2017年至2018年，其担任Juno Therapeutics执行委员会成员，并担任开发业务部执行副总裁，负责战略运营、定量科学、生物样品及临床业务。2018年至2019年，Sanders博士担任新基首席医疗官办公室的战略顾问。2019年至2020年，其担任百时美施贵宝全球开发小组过渡期临时顾问。自2019年至2024年12月，Sanders博士担任Molecular TemplatesInc.董事。自2020年至今担任Legend Biotech Corporation董事，自2021年6月至今担任Ultragenyx PharmaceuticalInc.董事。Sanders博士目前还担任AltruBioInc.的董事。
- Corazon D. Sanders,has served as director since May 2020. Dr. Sanders has been a member of AltruBio Inc. (f/k/a AbGenomics Holdings Inc.) since March 2020, of Beigene, Ltd since August 2020, and of Ultragenyx Pharmaceuticals, Inc. since June 2021. She was on the board of directors of Molecular Templates, Inc. from December 2019 to December 2024. Dr. Sanders previously served as a Strategic Advisor to the Office of the Celgene Chief Medical Officer from March 2018 to November 2019. Prior to that, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations from January 2017 to March 2018. Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2009 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017. Dr. Sanders also served on the Board of Trustees of the Fred Hutchinson Cancer Research Center and has been the co-chair of the board of Advisors of the newly created Fred Hutchinson Research Center since 2022. Dr. Sanders holds a B.S. and M.S. in statistics, graduating Magna Cum Laude from the University of the Philippines, and an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.
- Yau Wai Man Philip
-
Yau Wai Man Philip自2020年5月起担任我们的董事。尤先生是AMTD Group的非执行副主席，于2016年至2019年12月领导战略发展，企业融资和投资职能。从2011年到2016年3月，他曾任职Ernst&Young China Practice公司，担任合伙人、风险咨询中国南方市场领导者，在那里他曾为大中华地区的客户服务，在那里他曾建议财务、管理和业务问题。从2006年到2011年，他曾任职Protiviti Shanghai Co.，Ltd.，担任董事总经理兼深圳办事处负责人，在那里他主要负责公司的整体管理。从1997年到2006年，他曾任职普华永道会计师事务所（PricewaterhouseCoopers）和安达信会计师事务所（Arthur Andersen&Co.），最近担任风险咨询实践高级经理。Yau先生是美国注册会计师，香港会计师公会资深会员，以及内部审计师公会注册内部审计师。Yau先生拥有美国俄勒冈大学伦德奎斯特商学院（Lundquist College of Business）的会计学学士学位，以及西北大学凯洛格管理学院（Kellogg School of Management）和香港科技大学（Hong Kong University of Science and Technology）联合办学项目的执行工商管理硕士学位。
Yau Wai Man Philip,has served as director since May 2020. Mr. Yau has been the chief financial officer of C. & J. Clarks International Limited since October 2021. Prior to that, Mr. Yau worked at Ernst & Young China Practice as a partner, risk advisory China South market leader, serving clients in Greater China, where he advised on finance,management, and business issues and before that, he worked at Protiviti Greater China Practice as a managing director and Shenzhen office leader, where he was primarily responsible for overall management of the company. Mr. Yau served as a director of China General Education Group Limited, an education services company, from June 2021 until April 2022. Mr. Yau is a certified public accountant in the United States, a fellow member of the Hong Kong Institute of Certified Public Accountants, and a certified internal auditor with the Institute of Internal Auditors. Mr. Yau holds a B.A. in accounting from the Lundquist College of Business of University of Oregon in the United States and an Executive M.B.A. from a joint school program by Kellogg School of Management, Northwestern University and the Hong Kong University of Science and Technology. - Yau Wai Man Philip自2020年5月起担任我们的董事。尤先生是AMTD Group的非执行副主席，于2016年至2019年12月领导战略发展，企业融资和投资职能。从2011年到2016年3月，他曾任职Ernst&Young China Practice公司，担任合伙人、风险咨询中国南方市场领导者，在那里他曾为大中华地区的客户服务，在那里他曾建议财务、管理和业务问题。从2006年到2011年，他曾任职Protiviti Shanghai Co.，Ltd.，担任董事总经理兼深圳办事处负责人，在那里他主要负责公司的整体管理。从1997年到2006年，他曾任职普华永道会计师事务所（PricewaterhouseCoopers）和安达信会计师事务所（Arthur Andersen&Co.），最近担任风险咨询实践高级经理。Yau先生是美国注册会计师，香港会计师公会资深会员，以及内部审计师公会注册内部审计师。Yau先生拥有美国俄勒冈大学伦德奎斯特商学院（Lundquist College of Business）的会计学学士学位，以及西北大学凯洛格管理学院（Kellogg School of Management）和香港科技大学（Hong Kong University of Science and Technology）联合办学项目的执行工商管理硕士学位。
- Yau Wai Man Philip,has served as director since May 2020. Mr. Yau has been the chief financial officer of C. & J. Clarks International Limited since October 2021. Prior to that, Mr. Yau worked at Ernst & Young China Practice as a partner, risk advisory China South market leader, serving clients in Greater China, where he advised on finance,management, and business issues and before that, he worked at Protiviti Greater China Practice as a managing director and Shenzhen office leader, where he was primarily responsible for overall management of the company. Mr. Yau served as a director of China General Education Group Limited, an education services company, from June 2021 until April 2022. Mr. Yau is a certified public accountant in the United States, a fellow member of the Hong Kong Institute of Certified Public Accountants, and a certified internal auditor with the Institute of Internal Auditors. Mr. Yau holds a B.A. in accounting from the Lundquist College of Business of University of Oregon in the United States and an Executive M.B.A. from a joint school program by Kellogg School of Management, Northwestern University and the Hong Kong University of Science and Technology.
- Li Zhu
-
Li Zhu，自2020年11月起担任传奇生物技术公司董事。Zhu博士自2020年11月起担任金斯瑞首席战略官。此前，Zhu博士曾于2010年至2017年2月担任金斯瑞战略副总裁，于2017年2月至2019年7月担任金斯瑞首席战略官，并于2019年7月至2020年11月担任金斯瑞顾问。在加入Genscript之前，Zhu博士曾于1990年至2000年在Clontech Laboratories，Inc.担任分子生物学总监。Zhu博士创立了Genetastix公司，这是一家专注于基于酵母的抗体发现的生物技术公司，并在2000年至2005年期间担任总裁兼首席执行官。Zhu博士随后在中国的生物技术公司工作，2006年至2008年担任凯赛生物技术公司研究副总裁，2009年至2009年担任HUYA生物医药科技（上海）有限公司副总裁。Zhu博士拥有华东师范大学生物学学士学位和斯坦福大学分子生物学和免疫学博士学位。
Li Zhu,has served as director since November 2020. Dr. Zhu is the Chief Strategy Officer for Genscript since November 2020. Previously, Dr. Zhu was the Vice President of Strategy of Genscript from 2010 to February 2017, served as Chief Strategy Officer of Genscript from February 2017 to July 2019 and served as a consultant for Genscript from July 2019 to November 2020. Before joining Genscript, Dr. Zhu worked at Clontech Laboratories, Inc. as a Director of Molecular Biology from 1990 to 2000. Dr. Zhu founded Genetastix Corporation, Inc., a biotech company focused on yeast-based antibody discovery, and served as President and Chief Executive Officer from 2000 to 2005. Dr. Zhu then worked at biotech companies in China, serving as Vice President of Research at Cathay Biotech, Inc. from 2006 to 2008, and as vice president of HUYA Biomedical Technology (Shanghai) Co., Limited from 2009 to 2009. Dr. Zhu has served as a director of Genscript since November 2020 and as a director of Adagene Inc. since August 2023. Dr. Zhu holds a B.S. in biology from the East China Normal University and a Ph.D. in molecular biology and immunology from Stanford University. - Li Zhu，自2020年11月起担任传奇生物技术公司董事。Zhu博士自2020年11月起担任金斯瑞首席战略官。此前，Zhu博士曾于2010年至2017年2月担任金斯瑞战略副总裁，于2017年2月至2019年7月担任金斯瑞首席战略官，并于2019年7月至2020年11月担任金斯瑞顾问。在加入Genscript之前，Zhu博士曾于1990年至2000年在Clontech Laboratories，Inc.担任分子生物学总监。Zhu博士创立了Genetastix公司，这是一家专注于基于酵母的抗体发现的生物技术公司，并在2000年至2005年期间担任总裁兼首席执行官。Zhu博士随后在中国的生物技术公司工作，2006年至2008年担任凯赛生物技术公司研究副总裁，2009年至2009年担任HUYA生物医药科技（上海）有限公司副总裁。Zhu博士拥有华东师范大学生物学学士学位和斯坦福大学分子生物学和免疫学博士学位。
- Li Zhu,has served as director since November 2020. Dr. Zhu is the Chief Strategy Officer for Genscript since November 2020. Previously, Dr. Zhu was the Vice President of Strategy of Genscript from 2010 to February 2017, served as Chief Strategy Officer of Genscript from February 2017 to July 2019 and served as a consultant for Genscript from July 2019 to November 2020. Before joining Genscript, Dr. Zhu worked at Clontech Laboratories, Inc. as a Director of Molecular Biology from 1990 to 2000. Dr. Zhu founded Genetastix Corporation, Inc., a biotech company focused on yeast-based antibody discovery, and served as President and Chief Executive Officer from 2000 to 2005. Dr. Zhu then worked at biotech companies in China, serving as Vice President of Research at Cathay Biotech, Inc. from 2006 to 2008, and as vice president of HUYA Biomedical Technology (Shanghai) Co., Limited from 2009 to 2009. Dr. Zhu has served as a director of Genscript since November 2020 and as a director of Adagene Inc. since August 2023. Dr. Zhu holds a B.S. in biology from the East China Normal University and a Ph.D. in molecular biology and immunology from Stanford University.
- Patrick Casey
-
Patrick Casey，自2020年12月起担任传奇生物技术公司董事。自2005年以来，凯西博士一直担任杜克大学-新加坡国立大学医学院高级副院长和杜克大学James B. Duke药理学和癌症生物学教授。凯西博士还担任杜克大学医学中心的分子癌症生物学和生物化学助理教授，自1990年以来一直担任该职位。他也是杜克大学化学生物学中心的创始主任，该中心是一个由杜克大学科学家组成的组织，致力于研究和培训将基本化学原理应用于生物学研究以及疾病和疗法的基础。Casey博士拥有奥古斯塔纳大学生物和化学学士学位，生物化学博士学位
Patrick Casey,has served as director since December 2020. Dr. Casey has been the Senior Vice Dean of Research at the Duke-NUS Medical School and a James B. Duke Professor of Pharmacology and Cancer Biology at Duke University since 2005. Dr. Casey also serves as an Assistant Professor of Molecular Cancer Biology and Biochemistry at Duke University Medical Center, a position he has held since 1990. He was also the founding director of the Duke Center for Chemical Biology, an organization of Duke scientists dedicated to research and training in the application of fundamental chemical principles to the study of biology and the basis of disease and therapies. Dr. Casey holds a B.A. in biology and chemistry from Augustana University, a Ph.D. in biochemistry from the Brandeis University and did postdoctoral work at the University of Texas Southwestern Medical Center in Dallas. - Patrick Casey，自2020年12月起担任传奇生物技术公司董事。自2005年以来，凯西博士一直担任杜克大学-新加坡国立大学医学院高级副院长和杜克大学James B. Duke药理学和癌症生物学教授。凯西博士还担任杜克大学医学中心的分子癌症生物学和生物化学助理教授，自1990年以来一直担任该职位。他也是杜克大学化学生物学中心的创始主任，该中心是一个由杜克大学科学家组成的组织，致力于研究和培训将基本化学原理应用于生物学研究以及疾病和疗法的基础。Casey博士拥有奥古斯塔纳大学生物和化学学士学位，生物化学博士学位
- Patrick Casey,has served as director since December 2020. Dr. Casey has been the Senior Vice Dean of Research at the Duke-NUS Medical School and a James B. Duke Professor of Pharmacology and Cancer Biology at Duke University since 2005. Dr. Casey also serves as an Assistant Professor of Molecular Cancer Biology and Biochemistry at Duke University Medical Center, a position he has held since 1990. He was also the founding director of the Duke Center for Chemical Biology, an organization of Duke scientists dedicated to research and training in the application of fundamental chemical principles to the study of biology and the basis of disease and therapies. Dr. Casey holds a B.A. in biology and chemistry from Augustana University, a Ph.D. in biochemistry from the Brandeis University and did postdoctoral work at the University of Texas Southwestern Medical Center in Dallas.
- Li Mao
-
李茂，自2022年8月起担任传奇生物技术公司董事。毛博士目前担任SciClone Pharmaceuticals，Inc.的首席医疗官，自2022年6月起担任该职位。在此之前，毛博士于2021年5月至2022年6月担任中国生物制药股份有限公司首席医疗官，于2021年3月至2021年4月担任丽珠生物首席执行官，于2018年11月至2021年3月担任Xcovery Holdings，Inc.首席执行官。毛博士还曾于2018年3月至2021年3月担任贝达药业股份有限公司高级副总裁兼首席医疗官，并于2016年6月至2018年2月担任强生副总裁。此外，他于2004年至2009年3月担任MD安德森癌症中心教授，并于2009年3月至2016年6月担任马里兰大学巴尔的摩分校教授。毛博士还曾于2018年4月至2021年3月担任贝达药业股份有限公司董事会成员，该公司在深圳证券交易所上市。毛博士拥有南京医科大学医学博士学位。毛博士还在约翰·霍普金斯大学医学院完成了癌症遗传学的博士后研究。
Li Mao,has served as director since August 2022. Dr. Mao currently serves as President of R&D and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd., a position he has held since February 2025. Prior to that, he served as Chief Medical Officer for SciClone Pharmaceuticals, Inc. from June 2022 to February 2025. Prior to that, Dr. Mao served as Chief Medical Officer of Sino Biopharmaceutical Co., Ltd. from May 2021 to June 2022, Chief Executive Officer of Livzon Bio from March 2021 to April 2021 and Chief Executive Officer of Xcovery Holdings, Inc. from November 2018 to March 2021. Dr. Mao also served as Senior Vice President and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. from March 2018 to March 2021 and Vice President at Johnson & Johnson from June 2016 to February 2018. In addition, he served as a Professor at the MD Anderson Cancer Center from 2004 to March 2009 and a Professor at the University of Maryland, Baltimore from March 2009 to June 2016. Dr. Mao also served as a member of the board of directors of Betta Pharmaceuticals Co., Ltd, which is publicly listed on the Shenzhen Stock Exchange, from April 2018 to March 2021. Dr. Mao holds a Medical Doctor's degree from Nanjing Medical University. Dr. Mao also completed a postdoctoral fellowship in cancer genetics at The John Hopkins University School of Medicine. - 李茂，自2022年8月起担任传奇生物技术公司董事。毛博士目前担任SciClone Pharmaceuticals，Inc.的首席医疗官，自2022年6月起担任该职位。在此之前，毛博士于2021年5月至2022年6月担任中国生物制药股份有限公司首席医疗官，于2021年3月至2021年4月担任丽珠生物首席执行官，于2018年11月至2021年3月担任Xcovery Holdings，Inc.首席执行官。毛博士还曾于2018年3月至2021年3月担任贝达药业股份有限公司高级副总裁兼首席医疗官，并于2016年6月至2018年2月担任强生副总裁。此外，他于2004年至2009年3月担任MD安德森癌症中心教授，并于2009年3月至2016年6月担任马里兰大学巴尔的摩分校教授。毛博士还曾于2018年4月至2021年3月担任贝达药业股份有限公司董事会成员，该公司在深圳证券交易所上市。毛博士拥有南京医科大学医学博士学位。毛博士还在约翰·霍普金斯大学医学院完成了癌症遗传学的博士后研究。
- Li Mao,has served as director since August 2022. Dr. Mao currently serves as President of R&D and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd., a position he has held since February 2025. Prior to that, he served as Chief Medical Officer for SciClone Pharmaceuticals, Inc. from June 2022 to February 2025. Prior to that, Dr. Mao served as Chief Medical Officer of Sino Biopharmaceutical Co., Ltd. from May 2021 to June 2022, Chief Executive Officer of Livzon Bio from March 2021 to April 2021 and Chief Executive Officer of Xcovery Holdings, Inc. from November 2018 to March 2021. Dr. Mao also served as Senior Vice President and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. from March 2018 to March 2021 and Vice President at Johnson & Johnson from June 2016 to February 2018. In addition, he served as a Professor at the MD Anderson Cancer Center from 2004 to March 2009 and a Professor at the University of Maryland, Baltimore from March 2009 to June 2016. Dr. Mao also served as a member of the board of directors of Betta Pharmaceuticals Co., Ltd, which is publicly listed on the Shenzhen Stock Exchange, from April 2018 to March 2021. Dr. Mao holds a Medical Doctor's degree from Nanjing Medical University. Dr. Mao also completed a postdoctoral fellowship in cancer genetics at The John Hopkins University School of Medicine.
- Tomas Heyman
-
Tomas Heyman，自2022年8月起担任传奇生物技术公司董事。Heyman先生曾于2015年至2019年9月担任强生企业风险投资Capital Group总裁，该集团是全球医疗保健公司强生的风险投资部门，并于1992年至2015年担任强生制药集团业务发展全球主管。此外，海曼曾于2008年至2016年担任制药公司Janssen Pharmaceutica N.V.的首席执行官。Heyman先生自2020年12月起担任专业制药公司OptiNose公司董事，自2020年6月起担任生物技术公司Akero Therapeutics, Inc.董事，自2021年6月起担任生物制药公司Invivyd Inc.（原名Adagio Therapeutics公司）董事，自2022年9月起担任生物技术公司Xilio Therapeutics, Inc.董事。Heyman先生毕业于比利时K.U. Leuven大学，获得法律硕士学位。他继续在瑞士日内瓦攻读国际法研究生，并在比利时安特卫普大学攻读商业管理研究生。
Tomas Heyman,has served as director since August 2022. Mr. Heyman previously served as the President of Johnson & Johnson's Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a Global Healthcare Company from 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson's Pharmaceutical Group from 1992 to 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceutica N.V., a pharmaceutical company, from 2008 to 2016. Mr. Heyman has served as a director of OptiNose, Inc., a specialty pharmaceutical company, since December 2020, a director of Akero Therapeutics, Inc., a biotechnology company, since June 2020 and Exelixis Inc., an oncology company, since May 2023. Mr. Heyman previously served as a director of Invivyd Inc. (formerly known as Adagio Therapeutics Inc.), a biopharmaceutical company, from June 2021 to May 2024, and as a director of Xilio Therapeutics, Inc., a biotechnology company, from September 2022 to June 2024. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium. - Tomas Heyman，自2022年8月起担任传奇生物技术公司董事。Heyman先生曾于2015年至2019年9月担任强生企业风险投资Capital Group总裁，该集团是全球医疗保健公司强生的风险投资部门，并于1992年至2015年担任强生制药集团业务发展全球主管。此外，海曼曾于2008年至2016年担任制药公司Janssen Pharmaceutica N.V.的首席执行官。Heyman先生自2020年12月起担任专业制药公司OptiNose公司董事，自2020年6月起担任生物技术公司Akero Therapeutics, Inc.董事，自2021年6月起担任生物制药公司Invivyd Inc.（原名Adagio Therapeutics公司）董事，自2022年9月起担任生物技术公司Xilio Therapeutics, Inc.董事。Heyman先生毕业于比利时K.U. Leuven大学，获得法律硕士学位。他继续在瑞士日内瓦攻读国际法研究生，并在比利时安特卫普大学攻读商业管理研究生。
- Tomas Heyman,has served as director since August 2022. Mr. Heyman previously served as the President of Johnson & Johnson's Corporate Venture Capital Group, the venture capital arm of Johnson & Johnson, a Global Healthcare Company from 2015 to September 2019 and as the Global Head of Business Development for Johnson & Johnson's Pharmaceutical Group from 1992 to 2015. In addition, Mr. Heyman previously served as Chief Executive Officer of Janssen Pharmaceutica N.V., a pharmaceutical company, from 2008 to 2016. Mr. Heyman has served as a director of OptiNose, Inc., a specialty pharmaceutical company, since December 2020, a director of Akero Therapeutics, Inc., a biotechnology company, since June 2020 and Exelixis Inc., an oncology company, since May 2023. Mr. Heyman previously served as a director of Invivyd Inc. (formerly known as Adagio Therapeutics Inc.), a biopharmaceutical company, from June 2021 to May 2024, and as a director of Xilio Therapeutics, Inc., a biotechnology company, from September 2022 to June 2024. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
- Peter Salovey
-
彼得·萨洛维，自2024年8月起担任董事。Salovey博士是Chris Argyris心理学教授，此前曾担任耶鲁大学第二十三任校长，2013年7月至2024年6月担任校长。在成为总统之前，萨洛维博士曾担任耶鲁大学教务长、耶鲁学院院长、耶鲁大学艺术与科学研究生院院长。Salovey博士拥有斯坦福大学的A.B.（心理学）和A.M.（社会学）以及耶鲁大学的M.S.、M.Phil.和心理学博士学位。
Peter Salovey,has served as director since August 2024. Dr. Salovey is the Chris Argyris Professor of Psychology and previously served as the twenty-third president of Yale University, serving as President from July 2013 to June 2024. Before becoming president, Dr. Salovey served as Yale's provost, dean of Yale College, and dean of the Yale Graduate School of Arts and Sciences. Dr. Salovey holds an A.B. (psychology) and A.M. (sociology) from Stanford University and an M.S., M.Phil., and Ph.D. in psychology from Yale University. - 彼得·萨洛维，自2024年8月起担任董事。Salovey博士是Chris Argyris心理学教授，此前曾担任耶鲁大学第二十三任校长，2013年7月至2024年6月担任校长。在成为总统之前，萨洛维博士曾担任耶鲁大学教务长、耶鲁学院院长、耶鲁大学艺术与科学研究生院院长。Salovey博士拥有斯坦福大学的A.B.（心理学）和A.M.（社会学）以及耶鲁大学的M.S.、M.Phil.和心理学博士学位。
- Peter Salovey,has served as director since August 2024. Dr. Salovey is the Chris Argyris Professor of Psychology and previously served as the twenty-third president of Yale University, serving as President from July 2013 to June 2024. Before becoming president, Dr. Salovey served as Yale's provost, dean of Yale College, and dean of the Yale Graduate School of Arts and Sciences. Dr. Salovey holds an A.B. (psychology) and A.M. (sociology) from Stanford University and an M.S., M.Phil., and Ph.D. in psychology from Yale University.
高管简历
中英对照 | 中文 | 英文- Ying Huang
Ying Huang自2019年7月起担任我们的首席财务官。在加入我们之前，黄博士于2014年8月至2019年7月担任美国银行证券公司（BofA Securities，Inc.）董事总经理兼生物技术股票研究主管，在那里他领导了一支涵盖30多家生物技术公司的分析师团队，包括Amgen，Gilead，Celgene，Biogen和其他涵盖广泛治疗领域的药物。黄博士自2007年以来一直担任生物技术分析师，在加入美国银行证券公司（BofA Securities，Inc.）之前，曾在Wells Fargo（前身为Wachovia，Credit Suisse，Gleacher和Barclays）工作。在他的华尔街职业生涯之前，Huang博士是Schering-Plough（现Merck&Co.）化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。他也是多个专利和同行评议出版物的合著者。Huang博士拥有Columbia University生物有机化学博士学位。黄博士还曾就读于哥伦比亚商学院和中国科技大学天才青年特别班。
Ying Huang,has served as chief executive officer since September 2020 and previously served as chief financial officer from July 2019 until May 2022. Dr. Huang has also been a director of Quanta Therapeutics, Inc., a privately-held company, since February 2022. Prior to joining Legend Biotech Corporation , Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. In December 2021, Dr. Huang was appointed to board of directors as a Class I director.- Ying Huang自2019年7月起担任我们的首席财务官。在加入我们之前，黄博士于2014年8月至2019年7月担任美国银行证券公司（BofA Securities，Inc.）董事总经理兼生物技术股票研究主管，在那里他领导了一支涵盖30多家生物技术公司的分析师团队，包括Amgen，Gilead，Celgene，Biogen和其他涵盖广泛治疗领域的药物。黄博士自2007年以来一直担任生物技术分析师，在加入美国银行证券公司（BofA Securities，Inc.）之前，曾在Wells Fargo（前身为Wachovia，Credit Suisse，Gleacher和Barclays）工作。在他的华尔街职业生涯之前，Huang博士是Schering-Plough（现Merck&Co.）化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。他也是多个专利和同行评议出版物的合著者。Huang博士拥有Columbia University生物有机化学博士学位。黄博士还曾就读于哥伦比亚商学院和中国科技大学天才青年特别班。
- Ying Huang,has served as chief executive officer since September 2020 and previously served as chief financial officer from July 2019 until May 2022. Dr. Huang has also been a director of Quanta Therapeutics, Inc., a privately-held company, since February 2022. Prior to joining Legend Biotech Corporation , Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. In December 2021, Dr. Huang was appointed to board of directors as a Class I director.
- Carlos Santos
Carlos Santos，曾任阿斯利康美国肿瘤学首席财务官。在阿斯利康长达十年的任职期间，他还曾担任拉丁美洲（LATAM）代理地区副总裁和拉丁美洲地区首席财务官。他还在诺华的一个部门爱尔康工作了6年，在那里他担任过欧洲市场和巴西的首席财务官。近十年来，Mr. Santos一直在欧洲和拉丁美洲的英特尔公司担任财务领导职务。Mr. Santos在英国布里斯托大学获得了企业金融MBA学位。
Carlos Santos,was CFO for US Oncology at AstraZeneca. During his decade-long tenure at AstraZeneca, he also served as the Acting Area Vice President for Latin America (LATAM) and the Area CFO for LATAM. He also spent 6 years at Alcon, a division of Novartis, where he held CFO roles for European markets and Brazil. For nearly a decade, Mr. Santos held financial leadership positions at Intel Corporation in Europe and Latin America. Mr. Santos earned his MBA in Corporate Finance from the University of Bristol in the United Kingdom.- Carlos Santos，曾任阿斯利康美国肿瘤学首席财务官。在阿斯利康长达十年的任职期间，他还曾担任拉丁美洲（LATAM）代理地区副总裁和拉丁美洲地区首席财务官。他还在诺华的一个部门爱尔康工作了6年，在那里他担任过欧洲市场和巴西的首席财务官。近十年来，Mr. Santos一直在欧洲和拉丁美洲的英特尔公司担任财务领导职务。Mr. Santos在英国布里斯托大学获得了企业金融MBA学位。
- Carlos Santos,was CFO for US Oncology at AstraZeneca. During his decade-long tenure at AstraZeneca, he also served as the Acting Area Vice President for Latin America (LATAM) and the Area CFO for LATAM. He also spent 6 years at Alcon, a division of Novartis, where he held CFO roles for European markets and Brazil. For nearly a decade, Mr. Santos held financial leadership positions at Intel Corporation in Europe and Latin America. Mr. Santos earned his MBA in Corporate Finance from the University of Bristol in the United Kingdom.